促红细胞生成素治疗老年心力衰竭合并贫血的临床疗效及安全性  

Clinical efficacy and safety for erythropoietin in elderly patients with anaemia and heart failure

作　　者：张斌[1] 陈赛勇[1] 曲环[1] 

机构地区：[1]北京大学深圳医院心内科,广东深圳518036

出　　处：《中国临床药理学杂志》2016年第9期792-794,共3页The Chinese Journal of Clinical Pharmacology

基　　金：广东省科学研究基金资助项目(A2006607)

摘　　要：目的观察促红细胞生成素治疗老年心力衰竭合并贫血的临床疗效及安全性。方法 73例老年心力衰竭合并贫血患者随机分为对照组36例与试验组37例。对照组接受常规抗心力衰竭治疗,试验组在对照组的基础上口服铁剂200 mg,同时皮下注射促红细胞生成素,每次3000 IU,1周2次,疗程为4个月。观察2组患者治疗前后的脑钠肽、血红蛋白、左心室射血分数、左心室舒张末期内径、6 min步行距离及心血管不良事件发生率。结果试验组患者治疗后脑钠肽水平显著小于治疗前及对照组治疗后(P<0.05)。试验组患者治疗后血红蛋白、左心室射血分数及6 min步行距离均显著大于治疗前及对照组治疗后(P<0.05)。对照组治疗前后上述指标差异均无统计学意义(P>0.05)。对照组治疗后心血管事件发生率为27.78%,显著高于试验组的13.51%(P<0.05)。结论促红细胞生成素辅助治疗老年心力衰竭合并贫血可显著提高临床疗效,降低主要心血管不良事件的发生率。Objective To evaluated the clinical efficacy and safety of erythropoietin in the treatment of elderly patients with anaemia and heart failure. Methods A total of 73 patients with naemia and heart failure were randomly divided into control group（ n = 36） and treatment group（ n = 37）. Patients in control group were treated by regular regimen and patients in treatment group treated with ferrous sulfate 200 mg daily,plus subcutaneous injection of erythropoietin 3000 IU,2 times a week on the basis of control group. The brain natriuretic peptide（ BNP）,hemoglobin（ Hb）,left ventricular ejection fraction（ LVEF）,left ventricular end diastolic diameter（ LVDd）,6 min walking distance（ 6MWD） and incidence of major cardiovascular event of the two groups were compared.Results BNP was significant decreased in treatment group after treatment（ P〈0. 05）,and the Hb,LVEF and 6MWD significantly improved in treatment group compared with control group after treatment（ P〈0. 05）. There was no significant difference of control group before and after treatment（ P〉0. 05）. The incidences of major cardiovascular event were 27. 78% and 13. 51% in control and treatment groups with statistical difference（ P〈0. 05）. Conclusion Erythropoietin can improve the clinical efficacy and decrease the major cardiovascular event in thetreatment of elderly patients with anaemia and heart failure.

关 键 词：老年心力衰竭 贫血 促红细胞生成素 临床疗效 安全性 

分 类 号：R973[医药卫生—药品]